Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?

被引:3
|
作者
Dry, Sarah M. [1 ]
机构
[1] UCLA David Geffen Sch Med, Dept Pathol & Lab Med, 13-222 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA
关键词
Dedifferentiation; Chondrosarcoma; Liposarcoma; Chordoma; Parosteal osteosarcoma; Evidence-based; Diagnostic criteria; Grading; WELL-DIFFERENTIATED LIPOSARCOMA; PAROSTEAL OSTEOSARCOMA; CLINICOPATHOLOGICAL ANALYSIS; INTEROBSERVER VARIABILITY; CARTILAGINOUS TUMORS; CHONDROSARCOMA; GRADE; CHORDOMA; DIAGNOSIS; RELIABILITY;
D O I
10.1016/j.humpath.2024.02.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Dedifferentiation traditionally is defined by descriptive criteria as a tumor showing an abrupt change in histology from a conventional, classic, low-grade appearing neoplasm to a tumor that is more cellular, pleomorphic and "high grade", with grading typically being performed by subjective criteria. The dedifferentiated areas range from areas with recognizable histologic differentiation which differs from the primary tumor (such as an osteosarcoma arising from a low-grade chondrosarcoma) to areas containing sarcomas without specific histologic differentiation (such as pleomorphic or spindle cell sarcoma). Many, but not all, dedifferentiated tumors are aggressive and associated with significantly shorter survival than their conventional counterparts, even grade 3 conventional tumors. As a result, dedifferentiated tumors are generally considered to be clinically aggressive and as a result, more aggressive surgery or the addition of (neo)adjuvant chemotherapy is often considered. However, long-term (greater than 20 year) survivors are reported in the most common dedifferentiated bone and soft tissue sarcomas. Moreover, use of mitotic criterion for defining dedifferentiation in dedifferentiated liposarcoma as well as grading (by the French system) have been found to be associated with survival. This paper reviews the literature on dedifferentiated chondrosarcoma, dedifferentiated liposarcoma, dedifferentiated chordoma and dedifferentiated parosteal osteosarcoma. As a result of that review, recommendations are advocated to identify evidence-based, objective diagnostic and grading criteria for dedifferentiation that are appropriate for each tumor type. Adding such criteria will improve consistency in diagnosis worldwide, allow easier comparison of clinical research performed on dedifferentiated tumors and help communicate (to patients and clinicians) the tumors with highest risk of clinically aggressive behavior, to allow appropriate and personalized treatment planning.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [21] Morphometric Analysis Reveals Prognostically Distinct Groups of Undifferentiated Soft Tissue Sarcomas
    Zanfagnin, Valentina
    Gultekin, Okan
    Falcao, Raul Maia
    Lehti, Kaisa
    Petta, Tirzah Braz
    Carlson, Joseph
    LABORATORY INVESTIGATION, 2023, 103 (03) : S81 - S81
  • [22] How Do We Define Art?
    Andreev, Andrei L.
    Kuznetsova, Tatiana V.
    VOPROSY FILOSOFII, 2019, (08) : 72 - 79
  • [23] How do we define longevity?
    Maggio, JJ
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1999, 130 (01): : 20 - +
  • [24] How do we define masculinity?
    Newton, Faith
    PSYCHOLOGIST, 2019, 32 : 4 - 4
  • [25] Bone invasion in soft tissue sarcomas of the extremities: An underappreciated prognostic factor. Bone invasion in soft tissue sarcomas
    Yarih Garcia-Ortega, Dorian
    Alvarez-Cano, Alethia
    Angel Clara-Altamirano, Miguel
    Caro-Sanchez, Claudia
    De la Cruz Ruvalcaba-Gonzalez, Cuauhtemoc
    Cesar Cortes-Gonzalez, Carlo
    Luna-Ortiz, Kuauhyama
    SURGICAL ONCOLOGY-OXFORD, 2022, 40
  • [26] How do we define when we die?
    Donnelly, Seamas C.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (04) : 221 - 221
  • [27] Endogenous fructose production: what do we know and how relevant is it?
    Andres-Hernando, Ana
    Johnson, Richard J.
    Lanaspa, Miguel A.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2019, 22 (04): : 289 - 294
  • [28] Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
    Ozaniak, Andrej
    Vachtenheim, Jiri
    Lischke, Robert
    Bartunkova, Jirina
    Strizova, Zuzana
    BIOMEDICINES, 2021, 9 (08)
  • [29] Double hit lymphoma: How do we define it and how do we treat it?
    Merron, Bridgin
    Davies, Andrew
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (03) : 233 - 240
  • [30] Proton therapy in soft tissue and bone sarcomas
    Thariat, Juliette
    Tessonnier, Thomas
    Bonvalot, Sylvie
    Lerouge, Delphine
    Mammar, Hamid
    Bolle, Stephanie
    Claren, Audrey
    Duffaud, Florence
    Alapetite, Claire
    Vogin, Guillaume
    BULLETIN DU CANCER, 2018, 105 (09) : 830 - 838